“Growth Drivers and Opportunities for Biomarkers in
Healthcare”
24th September 2014
Sanjeev Kumar
Consultant
Global biomarkers market expected to exceed $40 billion by 2018 driven by
genomics
Genomics: CAGR of 26.9%
Imaging: CAGR o...
Biomarkers – How Important are they?
Identifying subgroups of patients (e.g. patient sub-groups, optimized patient
stratif...
Biomarkers are useful throughout the lifecycle of a medicine from target
identification to commercialization
Mobility
Serv...
Key Stakeholders in Biomarker industry
Part-Takers in Personalised
medicine- Biomarker pie
Pharmaceutical
Companies
Compan...
Technology Lifecycle Analysis
Total Biomarkers Market in Drug Discovery and Development: Technology Lifecycle Analysis,
Gl...
Biomarkers–Technology Capability
 Drug Discovery (Lead discovery/Optimization): A number of new targets can be identified...
Critical unmet needs and potential game-changing strategies
Critical Unmet Need Potential Game-changing Strategy
There is ...
Defining Future Healthcare Trends for Biomarkers
2
Biomarkers will find extensive demand in patient stratification applica...
Carrie Low
Corporate Communications
APAC
(+60) 3 6204 5910
Carrie.low@frost.com
Dr Siddharth Dutta
Industry Manager
Health...
Upcoming SlideShare
Loading in …5
×

Growth Drivers and Opportunities for Biomarkers in Healthcare

2,045 views

Published on

Frost & Sullivan presentation on growth drivers and opportunities for biomarkers in Healthcare

Published in: Business
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
2,045
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
48
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Growth Drivers and Opportunities for Biomarkers in Healthcare

  1. 1. “Growth Drivers and Opportunities for Biomarkers in Healthcare” 24th September 2014 Sanjeev Kumar Consultant
  2. 2. Global biomarkers market expected to exceed $40 billion by 2018 driven by genomics Genomics: CAGR of 26.9% Imaging: CAGR of 14.8% Proteomics: CAGR of 13.5% Bioinformatics: CAGR of 19.3% CAGR from 2013-2018
  3. 3. Biomarkers – How Important are they? Identifying subgroups of patients (e.g. patient sub-groups, optimized patient stratification) Understanding pathways and mechanisms Improved decision making in R&D (e.g. tools for profiling targets, compounds) Drivers for pharmaco-diagnostic development (e.g. increased benefit/ risk ratio, companion diagnostics) Biomarkers support navigation throughout the entire lifecycle of a medicine - from target identification to market
  4. 4. Biomarkers are useful throughout the lifecycle of a medicine from target identification to commercialization Mobility Service Providers Biomarkers Industry: Pharma and DiagnosticsAcademic: CROs CUSTOMER Applications Drug Discovery Technologies Indications • ‘Omics’ technologies o Genomics o Proteomics o Metabolomics o Others: Glycomics, Lipidomics • Imaging technologies • Bioinformatics • Drug discovery and development • Molecular diagnostics • Personalised medicine • Oncology • Cardiovascular diseases • Neurological disorders • Autoimmune disorders • Infectious diseases Total Biomarkers Market in Drug Discovery and Development: Market Overview, Global, 2013
  5. 5. Key Stakeholders in Biomarker industry Part-Takers in Personalised medicine- Biomarker pie Pharmaceutical Companies Companion Diagnostic Manufacturer Patients Physicians Payer Testing Laboratory Regulatory Authorities Stakeholders Benefits Patients Increases effectiveness of therapies Doctors Increases safety in treatment decision Healthcare Providers Better outcome at lower price Pharmaceutical Companies Regulatory approval and competitive advantages Diagnostic Companies New market opportunities
  6. 6. Technology Lifecycle Analysis Total Biomarkers Market in Drug Discovery and Development: Technology Lifecycle Analysis, Global, 2013 MaturityDevelopment Growth Decline Time SegmentValue Note: Bubble size represents market size; Imaging Metabolomics Proteomics Genomics
  7. 7. Biomarkers–Technology Capability  Drug Discovery (Lead discovery/Optimization): A number of new targets can be identified using biomarkers. Use of metabolomics and glycomics approaches are paving way for target identification, mainly for cancers and autoimmune diseases. Based on biomarker signatures, targeted personalized therapies can be developed. Biomarkers have enabled launch of many biologics that include Herceptin, Gleevec, Iressa, and Enbrel.  Pre-Clinical/Clinical Development: Identification of biomarkers that can be used as markers for response to therapy, and used in clinical trials, thus bringing down the costs and time of clinical trials. Prediction and detection of toxicity, efficacy in pre-clinical or clinical setting is easy with the use of biomarkers. Based on toxicities and efficacy levels, patient stratification is easier.  Clinical Management: Monitoring response to therapy (companion diagnostics) and Phase 4 (post marketing surveillance) can be regularized with the use of biomarkers. Changes in dose, drug type, and management of ADEs will be possible.  Diagnostics/Screening: Disease detection at early stages and screening for high-risk individuals . Overall reduction in healthcare costs with regular biomarker-based diagnostics.
  8. 8. Critical unmet needs and potential game-changing strategies Critical Unmet Need Potential Game-changing Strategy There is a need for a collaborative model that will enable companies to self- finance the demonstration of clinical utility and bring products to the market on time. • Collaboration with Pharmaceutical Companies • Marketing Direct-to-consumer (DTC) Stand-alone Diagnostics As no specific drug is involved in the development of diagnostic tests, diagnostic companies market these tests to healthcare providers directly. • Integration Model from Research to Commercialisation • Receive incentives for research and royalties, ranging from 2 to 3% on marketed products. • The second type is a combination of technology licensing and the demonstration of economic benefits. • The third type is a fully integrated stand-alone company Total Biomarker Market in Drug Discovery and Development: Game-changing Strategies, Global, 2013
  9. 9. Defining Future Healthcare Trends for Biomarkers 2 Biomarkers will find extensive demand in patient stratification applications, particularly for cardiac and neurological disorders. 3 An integrated systems biology approach for information analysis for biomarker discovery will be the key area of focus in future. 1 Evolving biomarkers will bring a paradigm shift in the way healthcare is provided - from the mere identification of drug targets to the optimisation of therapies.
  10. 10. Carrie Low Corporate Communications APAC (+60) 3 6204 5910 Carrie.low@frost.com Dr Siddharth Dutta Industry Manager Healthcare & Life Sciences (+60) 3 6204 5842 siddharth.dutta@frost.com Contact Us Jennifer Lazar Global Program Manager – Life Sciences +1 (650) 475 4560 jennifer.brice@frost.com Rhenu Bhuller Vice President, Healthcare, APAC (+65) 6890 0986 rbhuller@frost.com

×